RE: 6 biopsies. 100% with therapeutic levels of Dox28 Jan 2023 11:41
There's a school gate dad I know distantly, who manages a (modest sized, I assume) investment fund. I've never talked shares to him before now. However, on the strength of the results RNS (and emboldened by the sp rise that day) I finally felt confident enough to mention Avacta to him. Turns out that he doesn't invest in pharma stocks at all but a wife of his colleague does manage pharmas in her PF. So the message went out 'what does she think of Avacta?'.
I got a reply this morning. Turns out she's never even heard of Avacta. So maybe that's part of the problem with the reaction. Here's the email:
'My friend came back to me and said his wife has not heard about Avacta. I assume it is a small cap company that is not included in institutional portfolios.
In general, small caps in the pharma sector tend to be kind of binary stocks – you can make a lot of money or lose it all. Visibility on the success off new products is very low for non-experts. Hence, I think you should consider such investments a bit like betting on horses – can be fun but over the longer term rather does not make money.
All the best,' etc.
In my reply, thanking 'dad' for passing on the message, I've sent a link regarding the Science Day for the possible attn. of the pharma fund manager..